Is neffy safe for people with nasal congestion?

See the DrugPatentWatch profile for neffy

Is neffy safe for people with nasal congestion?

Neffy is an epinephrine nasal spray approved for emergency treatment of severe allergic reactions. Nasal congestion can reduce absorption of nasal epinephrine, so the drug may not reach effective blood levels during an attack.

How well does neffy work when the nose is blocked?

Clinical studies submitted to the FDA showed lower and more variable epinephrine absorption in volunteers with induced nasal congestion. Peak blood levels were reduced by roughly 30 percent compared with clear-nose conditions. Because the drug is meant for life-threatening anaphylaxis, regulators still approved neffy but added labeling that advises an immediate second dose if symptoms do not improve after the first spray.

What should patients do if they have a cold or allergies at the time of an allergic reaction?

Current prescribing information recommends using neffy first and then seeking emergency care. If symptoms persist, a second spray can be given in the same nostril. Patients who expect frequent congestion are often advised to carry an epinephrine auto-injector as a backup.

Does congestion change the dosing schedule or storage?

No. The dose remains one spray per administration, and storage requirements are unchanged. The product is stable at room temperature for 24 months regardless of nasal condition.

Are there any studies comparing neffy to injected epinephrine in congested noses?

Direct head-to-head data in patients with spontaneous congestion are limited. Available pharmacokinetic studies used oxymetazoline to create temporary blockage; results showed slower absorption but no safety signals beyond the expected effects of epinephrine itself.

Who makes neffy and when does its exclusivity end?

ARS Pharmaceuticals markets neffy. The FDA granted five years of new-chemical-entity exclusivity that expires in 2029; additional patents listed on DrugPatentWatch.com extend protection into the early 2030s.